Volume 10 Supplement 1
Hematopoietic stem cells for neovascularization and wound repair
© Iacopino et al; licensee BioMed Central Ltd. 2010
Published: 19 May 2010
It is now well-known that a critical part of normal healing for cutaneous wounds is the formation of new blood vessels. As implantation of autologous bone marrow (BM)-derived Endothelial Progenitor Cells (EPC) into ischemic limbs has become a promising treatment for moderate to severe peripheral arterial occlusive disease (PAD), we have begun a Phase II randomized trial in Type 2 diabetes mellitus (T2DM). The goal of infusions is to promote neoangiogenesis, thereby increasing circulation, reducing symptoms, and facilitating wound healing. At first, we have studied EPC and gene expression profile (GEP) of peripheral blood, hypothesizing that it is possible to identify useful markers for the assessment of the severity of endothelial dysfunction.
Methods and results
Using the high-performance flow cytometer FACSCanto, we analysed peripheral blood samples from diabetic patients and healthy donors. We found that T2DM did not affect the number of early EPC, but greatly decreased the number of highly differentiated EPCs. In addition, T2DM increases the presence of both live and dead circulating endothelial cells (CEC), together with an increase in the number of activated CEC.
Relative quantification of 96 genes (TaqMan® Low Density Array) has been investigated. Notably, GEP in T2DM was always different from that found in controls. In particular, patients showed abnormal expression of VEGFs, AFGs, MMPs, TIMPs, CXCL12, HIF-1 alpha, IL-8 and AMPK.
Computational intelligence methods (NeuCom, WWKNN and TWNFI) for discovering important information from biological data were used for PAD risk prediction.
Our results suggest that (i) the endothelial damage is due more to an altered process of maturation/commitment/homing of EPC than just to a simple decrease in their production, ii) CEC could be useful markers for the assessment of endothelial dysfunction severity, (iii) GEP allows early identification of the patients, at risk for PAD development, who might benefit of stem cell therapy.
This work was supported by Regione Calabria and Ministero della Salute, Italy
This article is published under license to BioMed Central Ltd.